A phase 3 study of the efficacy, safety, and pharmacokinetics profile of subcutaneous vs intravenous nivolumab + relatlimab fixed-dose combination in previously untreated metastatic or unresectable melanoma (RELATIVITY-127)
Titel:
A phase 3 study of the efficacy, safety, and pharmacokinetics profile of subcutaneous vs intravenous nivolumab + relatlimab fixed-dose combination in previously untreated metastatic or unresectable melanoma (RELATIVITY-127)
Auteur:
Long, G.V. Gutzmer, R. Haydon, A. Muñoz Couselo, E. Lebbé, C. Carlino, M. Chow, W. Couture, F. Lau, P. Spagnolo, F. Alves Wainstein, A.J. Palmieri, D. Rojas García, C. de Velasco Oria de Rueda, G. Mehmi, I. Patel, D. Shaikh, A. Chowdhury, N.R. Bathena, S. Suryawanshi, S. Rutkowski, P.